Literature DB >> 11882372

Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration.

M M Iravani1, K Kashefi, P Mander, S Rose, P Jenner.   

Abstract

The loss of dopaminergic neurones in the substantia nigra with Parkinson's disease may result from inflammation-induced proliferation of microglia and reactive macrophages expressing inducible nitric oxide synthase (iNOS). We have investigated the effects of the supranigral administration of lipopolysaccharide on iNOS-immunoreactivity, 3-nitrotyrosine formation and tyrosine hydroxylase-immunoreactive neuronal number, and retrogradely labelled fluorogold-positive neurones in the ventral mesencephalon in male Wistar rats. Following supranigral lipopolysaccharide injection, 16-18 h previously, there was intense expression of NADPH-diaphorase and iNOS-immunoreactivity in non-neuronal, macrophage-like cells. This was accompanied by intense expression of glial fibrillary acidic protein-immunoreactive astrocytosis in the substantia nigra. There were also significant reductions in the number of tyrosine hydroxylase(50-60%)- and fluorogold (65-75%)-positive neurones in the substantia nigra. In contrast, tyrosine hydroxylase-immunoreactivity in the ventral tegmental area was not altered. Pre-treatment of animals with the iNOS inhibitor, S-methylisothiourea (10 mg kg(-1), i.p.), led to a significant reduction of lipopolysaccharide-induced cell death. Similar reduction of tyrosine hydroxylase-immunoreactivity and fluorogold-labelled neurones in the substantia nigra following lipopolysaccharide administration suggests dopaminergic cell death rather than down-regulation of tyrosine hydroxylase. We conclude that the expression of iNOS- and 3-nitrotyrosine-immunoreactivity and reduction of cell death by S-methylisothiourea suggest the effects of lipopolysaccharide may be nitric oxide-mediated, although other actions of lipopolysaccharide (independent of iNOS induction) cannot be ruled out.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11882372     DOI: 10.1016/s0306-4522(01)00562-0

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  65 in total

Review 1.  Neuroprotection in Parkinson's disease: an elusive goal.

Authors:  William C Koller; Maria G Cersosimo
Journal:  Curr Neurol Neurosci Rep       Date:  2004-07       Impact factor: 5.081

Review 2.  Role of glial cells in neurotoxin-induced animal models of Parkinson's disease.

Authors:  Hironori Yokoyama; Hiroto Uchida; Hayato Kuroiwa; Jiro Kasahara; Tsutomu Araki
Journal:  Neurol Sci       Date:  2010-11-24       Impact factor: 3.307

Review 3.  Therapeutic Potential of Baicalein in Alzheimer's Disease and Parkinson's Disease.

Authors:  Yanwei Li; Jinying Zhao; Christian Hölscher
Journal:  CNS Drugs       Date:  2017-08       Impact factor: 5.749

4.  Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.

Authors:  Belén G Ramírez; Cristina Blázquez; Teresa Gómez del Pulgar; Manuel Guzmán; María L de Ceballos
Journal:  J Neurosci       Date:  2005-02-23       Impact factor: 6.167

5.  The effects of age and lipopolysaccharide (LPS)-mediated peripheral inflammation on numbers of central catecholaminergic neurons.

Authors:  P R Mouton; B Kelley-Bell; D Tweedie; E L Spangler; E Perez; O D Carlson; R G Short; R deCabo; J Chang; D K Ingram; Y Li; N H Greig
Journal:  Neurobiol Aging       Date:  2010-11-19       Impact factor: 4.673

6.  Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease.

Authors:  R Lee Mosley; Eric J Benner; Irena Kadiu; Mark Thomas; Michael D Boska; Khader Hasan; Chad Laurie; Howard E Gendelman
Journal:  Clin Neurosci Res       Date:  2006-12-06

Review 7.  Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention.

Authors:  Malú G Tansey; Melissa K McCoy; Tamy C Frank-Cannon
Journal:  Exp Neurol       Date:  2007-07-17       Impact factor: 5.330

8.  Metabotropic glutamate receptor 5 activation inhibits microglial associated inflammation and neurotoxicity.

Authors:  Kimberly R Byrnes; Bogdan Stoica; David J Loane; Angela Riccio; Margaret I Davis; Alan I Faden
Journal:  Glia       Date:  2009-04-01       Impact factor: 7.452

Review 9.  Antioxidants in central nervous system diseases: preclinical promise and translational challenges.

Authors:  Chandrashekhar D Kamat; Sunyana Gadal; Molina Mhatre; Kelly S Williamson; Quentin N Pye; Kenneth Hensley
Journal:  J Alzheimers Dis       Date:  2008-11       Impact factor: 4.472

Review 10.  Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria.

Authors:  Guy C Brown; Anna Bal-Price
Journal:  Mol Neurobiol       Date:  2003-06       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.